Teva's CEO Presents At Barclays Capital Global Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited (TEVA)

Barclays Capital Global Healthcare Conference

March 13, 2012 4:15 PM ET

Executives

Bill Marth – Chief Executive Officer

Analysts

Doug Tsao – Barclays Capital

Presentation

Doug Tsao – Barclays Capital

Compare to:
Previous Statements by TEVA
» Teva Pharmaceutical Industries' Management Presents at Citi Global Health Care Conference (Transcript)
» Teva Pharmaceutical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Teva Pharmaceutical Industries Management Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)

So, good afternoon, everybody. My name is Doug Tsao. I cover U.S. Spec Pharma here at Barclays Capital. With us now is Bill Marth, CEO of Teva Americas. Obviously, I think almost everybody in the room is very familiar with Teva, which is the largest generics manufacturer in the world, as well as a leading brand player as well and certainly, increasingly so and certainly, part of the strategic direction for the company is to diversify the model. So, I think that will obviously be sort of a point of our conversation.

So to start off with, Bill, I think with a lot of the generics manufacturers who we’ve had present today, sort of started with this one question is, how you see your company, as well as the generics industry in the post-patent cliff world, which is certainly a concern that many people and investors sort of relate to me and ask me questions about, and I just wanted to get your perceptions on how Teva can successfully navigate that landscape?

Bill Marth

Well, thanks for the question, Doug. I think it’s really an interesting question and it’s a lot about your strategy as a company. Teva is really a company that is well-balanced between brand and generic. Our goal or our mission we feel is really to bring medications to patients around the world.

1 2 3 Next › Last »